Drug Profile
Thykamine - Devonian
Alternative Names: PCT-233; PUR-0110; Thykamine™Latest Information Update: 22 Nov 2023
Price :
$50
*
At a glance
- Originator PurGenesis Technologies
- Developer Devonian
- Class Anti-inflammatories; Antiacnes; Cardiovascular therapies; Radioprotectives; Skin disorder therapies
- Mechanism of Action Antioxidants; Cytokine inhibitors; Interleukin 10 modulators; Reactive oxygen species inhibitors; Tumour necrosis factor alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Ulcerative colitis
- Phase I Erythrodysaesthesia; Radiodermatitis
- Discontinued Acne; Cardiovascular disorders; Psoriasis